We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluation of the Impact of Ritlecitinib on Organic Cation Transporters Using Sumatriptan and Biomarkers as Probes.
- Authors
Wang, Xiaoxing; Purohit, Vivek; Dowty, Martin E.; Rodrigues, David; Luo, Lina; Mathialagan, Sumathy; Carey, William; Plotka, Anna; Kalluru, Hindu; Melissa, O'Gorman; Kaplan, Julia; Huh, Yeamin; Vourvahis, Manoli; Wolk, Robert M.
- Abstract
Ritlecitinib, an inhibitor of Janus kinase 3 and hepatocellular carcinoma family kinases, is in development as potential treatment for several inflammatory diseases. In vitro studies presented ritlecitinib as an inhibitor of hepatic organic cation transporter (OCT) 1, renal transporters OCT2 and multidrug and toxin extrusion (MATE) proteins 1/2K using multiple substrates, and ritlecitinib's major inactive metabolite M2, as an inhibitor of OCT1. A clinical interaction study with an OCT1 drug probe (sumatriptan) and relevant probe biomarkers for OCT/MATE was conducted to assess the effect of ritlecitinib on these transporters in healthy adult participants. The selectivity of sumatriptan for OCT1 was confirmed through a series of in vitro uptake assays. A simple static model was used to help contextualize the observed changes in sumatriptan area under the plasma concentration‐time curve (AUC). Coadministration of a single 400‐mg dose of ritlecitinib increased sumatriptan AUC from time 0 to infinity (AUCinf) by ≈30% relative to a single 25‐mg sumatriptan administration alone. When administered 8 hours after a ritlecitinib dose, sumatriptan AUCinf increased by ≈50% relative to sumatriptan given alone. Consistent with OCT1 inhibition, the AUC from time 0 to 24 hours of isobutyryl‐L‐carnitine decreased by ≈15% after ritlecitinib. Based on the evaluation of the renal clearance of N1‐methylnicotinamide, ritlecitinib does not exert clinically meaningful inhibition on renal OCT2 or MATE1/2K. This study confirmed that ritlecitinib and M2 are inhibitors of OCT1 but not OCT2 or MATE1/2K in healthy adults.
- Subjects
BIOMARKERS; IN vitro studies; JANUS kinases; RESEARCH funding; DRUG interactions; NEUROTRANSMITTER uptake inhibitors; CATIONS; SUMATRIPTAN; CARRIER proteins; PATIENT safety
- Publication
Journal of Clinical Pharmacology, 2023, Vol 63, Issue 7, p784
- ISSN
0091-2700
- Publication type
Article
- DOI
10.1002/jcph.2215